Global footprint Poly Medicure operates in over 100 countries with a diverse product portfolio spanning infusion therapy, central venous catheters, blood management, surgery and wound drainage, anesthesia, urology, gastroenterology and dialysis, presenting multiple cross-sell and regional expansion opportunities for distributors and hospital procurement teams.

R&D and patents With 215+ granted patents and 250+ patents filed, the company demonstrates strong innovation, enabling sales pitches around advanced consumables, differentiated products like drug-eluting stents, and potential collaboration on clinical trials and high-end cardiovascular devices.

Manufacturing scale Five domestic and three overseas manufacturing facilities, plus plans for two new facilities, support scalable supply commitments, faster lead times, and reliability for large hospital systems and government tenders seeking consistent inventory and local production.

Strategic growth Recent acquisitions and expansions, including the Citieffe Group acquisition and new product launches across critical care, cardiology, oncology and vascular access, indicate a growth trajectory with opportunities to cross-sell high-value devices and secure regional distribution agreements.

Leadership and vision New leadership in Asia Pacific and India, aggressive product rollout goals, and a clear focus on sustainability initiatives such as solar partnerships position Poly Medicure as a forward-looking supplier, suitable for multi-year procurement programs and ESG-aligned tenders.